China in the Fast Lane - How to play and win in the world's hottest emerging market
Watch this webcast in which Pei Li Teh and Wan Ling Neo explore China's evolving healthcare environment. In this webcast they highlight the key changes affecting pharma and demonstrate how to build the market understanding required to launch a brand effectively in this exciting region.
Usability and UX: You’ve been asked to test… what next?
The healthcare industry is increasingly using digital channels to deliver information and services to its customers. However, for these to be effective and increase brand satisfaction, it’s critical that patients, HCPs, and any other stakeholders have a positive user experience.
MRX time machine: How to use time series forecasting to improve your demand assessment
In the second part of our Innovation in #MRX series we demonstrate how to use time series forecasting to better inform product uptake and competitive scenarios up to 10 years into the future.
Understanding likely demand for a new product or service is essential to help develop the right brand strategy. Techniques such as conjoint and fixed product profile assessments are great for evaluating the market landscape and opportunity, but are they enough? Can we predict the future with greater accuracy? Time series forecasting is one of the latest market research innovations we have been championing at Research Partnership and we would like to share the benefits of this technique with you.
China in the Fast Lane: How to play and win in the world's hottest emerging market
Watch this webcast where Marc Yates and Helen Ansell explore China's evolving healthcare environment. The webcast highlights the key changes affecting pharma and demonstrates how to build the market understanding required to launch a brand effectiviely in this exciting region.
Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorum
Rheumatoid arthritis (RA) has been a major growth driver for the pharmaceutical industry over the last 15 years, led by AbbVie’s blockbuster anti-TNF inhibitor treatment Humira (adalimumab).